DR AGENA OBGYN DRIVERS
DR AGENA OBGYN DRIVER
DR AGENA OBGYN SERIES

This level of respect and empathy is given to every patient no matter what their needs. For new patients, especially for parents with daughters coming in for their first visit, he believes it is important to have a one-on-one consultation to help the patient (and parents) get to know him, express their concerns and feel at ease.

Agena intentionally keeps his practice small so that he can personally connect with his patients throughout all stages of their reproductive lives. Cardio vascular diseases account for an estimated 17.5 million people in 2012, representing one third of all global deaths.Īt Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.Celebrating the practice’s one-year anniversary this June, Dr. The World Cancer Report, of World Health Organization predicts 50% rise in cancer rates by 2020 which represents 15 million new cases.

DR AGENA OBGYN DRIVER

The critical demographic driver of the market is the rise in incidence of cancer and other diseases coupled with growing risk factors such as tobacco use, infections such as hepatitis, human papillomavirus (HPV) etc., exposure to ionizing radiation and others. Further real time molecular assessment afforded by liquid biopsy allows designing treatment strategies based on the disease progression. For instance Pathway Genomics and Guardant360 offered liquid biopsy test for cancer at $299 and $5,800 respectively. However liquid biopsy tests are available for less than 6000 USD. dollars, which may increase due to high failure rate of approximately 25%. Tissue biopsies cost around $15,000 to $60,000 U.S. Tissue biopsy has drawbacks such as low detection rate, is expensive and needs approximately 30 days compared to 12 days for liquid biopsy.

DR AGENA OBGYN DRIVERS

The clinical drivers of the market include painless and non-invasive technique, early high precision detection of diseases. Sample – blood, urine and others.Įnd Users – hospitals and laboratories, academic and research centers and others. To give an accurate assessment of the differential potential of the market the report is divided into segments such as biomarker type, application, end users and regions.īiomarker type – circulating tumor cells (CtCs), extracellular vehicles (EVS), circulating tumor DNA (CtDNA), and other biomarker.Īpplication – reproductive health, cancer therapeutic application, and other therapeutic application. The prominent players in the global liquid biopsy market are Guardant Health, Inc., Agena Bioscience Inc., Trovagene Inc., Circulogene Theranostics, Admera Health, RainDance Technologies, Biocept, Inc., Exosome Diagnostics and others. Vascular diseases such as lung cancer, cardiovascular diseases are expected to result in impressive growth. He further estimated lend and lease agreements would benefit both the players and clients, as it will relieve clients of paying a large upfront sum, which it allows the companies a steady revenue and beat competition from other players. Suhail Noolkar, researcher at Market Research Future. The high cost of installation and maintenance of liquid biopsy is a deterrent especially for smaller hospitals which do not possess the buying power says Mr. Lend and lease business model is expected to deliver faster market adoption.

DR AGENA OBGYN SERIES

GRAIL diagnostics raised approximate USD 900 million in a series of financing rounds which is estimated to double in the next stage of rounds.īusiness models are as important as the test itself! For example, Exact Sciences generated an approximate 150 % increase over its 2015 revenues, on account of excellent performance and faster market uptake of its colorectal cancer test Cologuard. The liquid biopsy industry has generated spectacular results culminating in large startup funding. Spectacular revenue growths attracting startup funding The global liquid biopsy market is anticipated to generate USD 1.7 billion by 2022, and growing by a rocking CAGR of 28%. for the detection of diseases such as cancer, cardiovascular, and other ailments. Liquid biopsy provides a non-invasive test using liquid samples such as blood, urine, etc. A liquid biopsy is a diagnostic application occurring from the advances in human genome sequencing and molecular biomarkers.

Dr agena obgyn